IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Fecal Microbiota Transplantation As An Emerging Therapeutic Modality For Clostridium Difficile Infection

[1]Saumya Singh, [2]Diya Gupta, [3]Anshita Singh, [4]Ashish Ranjan Singh, [5]Swati Bajpai

Department of Biotechnology
Kanpur Institute of Technology
Kanpur, Uttar Pradesh-208001 India

ABSTRACT:

A serious issue is antibiotic resistant infections because they lead to increased illness, more deaths and more expensive care. Since conventional antibiotics are ineffective in case of these powerful bacteria, there is a big need for new ways to treat diseases. Probiotics in our gut become unbalanced, it can make us unwell. One method, called Fecal microbiota transplantation (FMT), involves giving healthy gut bacteria from one person to another. This method has been very useful in rebalancing of gut bacteria. FMT has demonstrated high efficacy in treating recurrent infections caused by Clostridioides difficile by helping to increase the variety of bacteria, control the body's chemistry, prevent harmful bacteria from overpowering, and make the gut stronger. Numerous studies suggest that this treatment works most of the time and is usually safe, but there are still some problems to solve, like making sure the process is done the same way each time, checking donors carefully, and understanding if there are prolonged threats. The aim of this review is to evaluate how well FMT works, how it affects the body, the situations where it is used, and the challenges that still exist. Additional study is necessary to make FMT better, keep it safe, and use it for more kinds of diseases that are related to the gut bacteria and antibiotic resistance .

Keywords- Fecal Microbiota Transplantation, Clostridioides *difficile* infection, Antibiotic-Resistant Infections, Gut microbiota, Probiotics

1. INTRODUCTION

FMT is an emerging treatment used to transfer stool from healthy donor into the gut of patient. It is efficient in curing recurrent CDI [1] . This technique can be carried out through colonoscopy, nasogastric/nasoenteric tubes, or an enema [2].

Acute CDI symptoms comprises steatorrhea, peripheral leukocytosis, elevated C-reactive protein (CRP), and acute kidney injury [3]. Clostridioides difficile causes a bacterial disease, Clostridioides difficile infection [4]. After the repeated use of antibiotics that creates disbalance in the gut microbiota, it impacts colon admitting C. difficile to proliferate and produce toxins that harm the intestinal lining. Emerging data suggests that the CDI is mainly caused due to dysbiosis, an imbalance in the normal gut microbiota.

FMT aims to eliminate Clostridioides difficile while also substantially providing to the regain of microbial diversity and upgrade the gastrointestinal tract [5]. The occurrence of CDI in India has been noted to vary between 3.4% and 18%, reflecting a significant burden of the illness. FMT is an extremely effective therapy for CDI, attaining cure rates of up to 91% in a month and 88% at eight weeks, mostly in severe and recurrent instances as shown in the study undertook in India [6].

FMT has displayed potential in addressing issues like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), though further studies are required to confirm its effectiveness for these therapies [7]. FMT's

effectiveness in India for CDI and various gastrointestinal issues enhances its potential in addressing antibiotic-resistant infections and its increasing significance in clinical care.

Throughout the duration of the study period, an increase in the occurence of CDI was observed in all pediatric age groups showing that this infection affects the younger people . Infants less than 1 year old consistently had the highest rates of CDI, initiating from approximately 5.0 per 1,000 hospitalizations in 1997 and increasing steadily to around 9.0 per 1,000 hospitalizations by the year 2006. The high rates in this age group may suggest factors such as immature gut flora, increased antibiotic exposure, and high hospitalization rates. Children between the age 1 to 4 years have shown a rise in the incidence rates from 3.0 to 6.5 cases per 1000 hospitalizations. The children aged between 5 to 9 year showed an increase in CDI cases from about 2.5 to 5.5 per 1000 and the age group ranging from 10 to 14 years showed a rise in cases from about 1.5 to 3.5 per 1000. Notably, the surge was clearer after 2003 in teenagers between the age 15 and 17 years, going up from below 2.0 to 4.5 cases per 1,000 to nearly 5.0 per 1,000 in 2006 [8].

This CDI infection has become a serious problem amongst infants and teenagers as shown in recent reasearch. It emphasizes the necessity for more efficient and sustainable therapeutic approaches. Due to the constraints of antibiotic treatments in controlling recurrent CDI, Fecal Microbiota Transplantation (FMT) presents a hopeful treatment option. Studies indicate that FMT is very effective in regaining gut microbiota equilibrium and lowering recurrence rates, implying possible usefulness in pediatric environments where CDI rates are increasing [8].

2. CLINICAL EVIDENCE SUPPORTING FMT

2.1 Early Studies on FMT (2010–2013)

An 81% of cure rate was observed after the single treatment by FMT whereas vancomycin showed a cure rate of 31, during a significant random trial. This major finding validated that FMT is an extremely effective treatment for recurrent CDI [1].

2.2 Safety and Adverse Events

FMT is regarded as safe, with the majority of adverse events like mild diarrhea or abdominal pain resolving promptly [6]. Nevertheless, unusual yet severe complications, like bacteremia, have arisen from inadequate donor screening [9].

2.3 Standardization and Regulation

FMT does not have globally recognized procedure for the selection of donors, preparing stool, or methods of delivery. The FDA supervises how FMT is used and makes sure that the patients give informed consent [10]. European clinical guidelines likewise stress highly standardized protocols [2].

2.4 Clinical Outcomes and Global Trends

Through FMT a cure rate of 80-90% was consistently demonstrated which is higher than traditional antibiotics [11]. Active treatments can boost success even more. The CDI rates are increasing globally, especially in hospitalized and immunocompromised individuals [12].



fig 1. comparative analysis of pediatric CDI rates in 1997 and 2006

.

3.MECHANISM OF ACTION OF FECAL MICROBIOTA TRANSPLANTATION (FMT)

The ability of FMT to restore a varied and diverse gut microbiota which is essential for preventing dysbiosis and keeps the gut balanced. A key mechanism by which FMT produces the results is the restoring microbial diversity, substituting dysbiotic bacterial communities with a complex and well-balanced group of advantageous microorganisms. This reinstated diversity boosts colonization resistance and inhibits the growth of Clostridioides difficile and other opportunistic pathogens [13&14].

A different key mechanism pertains to the control of bile acid metabolism. In a dysbiotic gut, primary bile acids build up and encourage C. difficile spore activation. Following FMT, microbes from the donor transform primary bile acids into secondary bile acids, which suppress C. difficile growth and toxin generation, consequently reducing the chance of infection recurrence [14]. This change in metabolic function is a key factor for the success of FMT.

FMT also restores production of the short chain fatty acids (SCFAs) including butyrate, acetate, and propionate. These metabolites promote intestinal health through mechanisms including the acidification of luminal pH, enhancing epithelial cell energy metabolism, promotion of regulatory immune cells, and suppression of pathogenic bacteria [15]. The increased SCFA production enhances mucosal integrity and promotes long-term resilience of the gut ecosystem.

Another important mechanism is represented by immune modulation FMT helps the body's immune system by reducing inflammation, helping T Cells function better and improving the gut's immune barrier. Restored microbial communities stimulate the production of antimicrobial peptides and maintain equilibrium within the gut-associated lymphoid tissue, which, in turn, helps avoid further pathogenic colonization [4].

Importantly, FMT enhances the intestinal barrier integrity. Dysbiosis is known to disrupt the tight junctions of epithelia and making the intestine more permeable, allowing the access of toxins and pathogens to the systemic circulation. FMT secures tight junction proteins and reduces gut permeability by the replenishment of the gut with healthy microbiota, thereby enhancing epithelial healing with less inflammation [15].

Finally, FMT acts through direct competitive exclusion of pathogenic organisms. The introduced donor microbes occupy ecological niches and compete with the available nutrients, further producing antimicrobial metabolites, thereby making conditions unfavorable for the growth and colonization of pathogens like C. difficile.Through increased metabolic cooperation in the restored microbiota this competitive effect is reinforced, thus enhancing community stabilization and resilience [16].

In general, the mechanism of FMT involves a complex interplay among the restoration of the microbiota, metabolic regulation, immune modulation, epithelial repair, and competitive inhibition of pathogens. These combined effects explain its high therapeutic success in recurrent CDI and increasing potential regarding various microbiome-associated diseases.

4. FECAL TRANSPLANTATION METHODS INCLUDE:

4.1 Colonoscopy

A colonoscopy is done by inserting a thin tube along with a small camera attached, into the colon through the rectum, which provides healthcare providers with a visual of the inside of the intestine; treatments can also be administered via the tube, including fecal microbiota transplantation [2].

4.2 Upper endoscopy

In the process of upper endoscopy a tube called endoscope is gently put in through the mouth or nose, down the esophagus, and into the stomach or small intestine. This acts as an alternative to colonoscopy, but due to the the necessity for the microbiota to travel through the small intestine to get to the colon it has a much lower success rate [12].

4.3 Enema

The tube is inserted into the rectum as part of this enema to allow therapeutic agents to be delivered, for the purposes of allowing the fecal microbiota to migrate with very minimal disruption of the environment in the colon, versus in the small intestine. Administered via this route of administration is the FDA-approved fecal microbiota therapy Rebyota, also known as RBL [17].

4.4 Oral capsule

Fecal transplant pills are capsules containing freeze-dried, live fecal microbiota. The capsules are designed to stay intact until they reach the colon. The most recent FDA-approved fecal microbiota therapy, SER-109 — an oral capsule called VOWST™ (fecal microbiota spores, live-brpk) — contains specific fecal-sourced microbial spores [18].

5. LIMITATIONS OF FECAL MICROBIOTA TRANSPLANTATION (FMT)

There are still some limitations that affects how widely FMT can be used in treating recurrent CDI . The first issue is a lack of standardization in procedures; so far, no single approach regarding donor selection, stool preparation, microbial processing, or administration techniques has been uniformly accepted as the standard, which increases variability in treatment outcomes across different centers. The second is that pathogen transmission remains a risk. Given that donors are highly selected based on medical and laboratory screening, there remains a very low but real possibility of transferring undetected infectious agents or multidrug-resistant organisms to recipients, as mentioned in reported cases following FMT-induced bacteremia [9].

Another issue is that the effects of adding another person's microbiota to the gut are still unclear. The FDA and other regulatory bodies have pointed out that the unknown long-term impact due to altered gut microbiota is itself a source of concern regarding the safety aspects, which demands further research and monitoring [10]. All these issues therefore create a demand for the stronger regulatory regime, better screening technology, and standardized clinical guidelines to ensure safety and efficacy of FMT.

6. DISCUSSION

FMT is one of the most effective ways to manage rCDI, particularly when antibiotic treatment fails to restore normal microbial flora. A large body of clinical evidence has indicated that rCDI is essentially caused by severe dysbiosis, and the principle of FMT directly targets this mechanism through the reintroduction of a diverse community into the gut [4& 13] . This newly restored microbial diversity enhances colonization resistance and suppresses the overgrowth of C. difficile due to competitive exclusion, enhanced short-chain fatty acid production, and interference with bile acid metabolism . These provide some scientific explanations[14 &15] for the remarkably high cure rate with FMT, consistently exceeding 80–90% in rCDI cases in various clinical settings [11 &1].

Apart from CDI, FMT can be used to treat other diseases related to gut imbalance like IBS, IBD and infections that are resistant to many medicines [5&7] . Although initial results are encouraging, outcomes in these disorders are variable; this is likely due to heterogeneity in disease pathophysiology, donor–recipient microbial compatibility, and host immunoresponses. Variability here thus calls for larger, well-controlled clinical trials. These should define patient subgroups likely to benefit most and the particular microbial functions responsible for therapeutic success.

In spite of being effective in treating CDI , various barriers inhibit the wide range of applications in clinical settings. The absence of strict protocols for screening of donor , processing of tools,handling of microbes and the way it is administered has resulted in variations in clinical approaches [2 &19] . In relation to the possible spread of hidden pathogens or organisms resistant to antimicrobial treatment, concerns about safety protocols have arised as shown in recorded instances of infections following FMT [9]. These occurrences highlight the significance of thorough donor evaluation, sophisticated pathogen testing, and robust regulatory supervision. On the whole, researches have shown evidence that FMT is a highly effective treatment for recurrent CDI and a potential new treatment for other gut-related conditions in the future. To guarantee safe, uniform, effective

results among various patient groups enhanced its application will demand standardized clinical protocols, extensive safety research, and more defined regulatory structures.

7. CONCLUSION

Cure rates achieved through fecal microbiota transplantation have consistently shown to be superior than those of conventional antibiotic treatments. Its success is mainly due to its capability to rectify the significant dysbiosis typical of recurrent CDI, reinstating microbial diversity, managing bile acid metabolism, boosting colonization resistance, and fortifying intestinal barrier function Clinical research in various environments has shown cure rates of 80–90%, solidifying FMT as the favored approach for recurrent CDI, especially in situations where antibiotic treatments often fail.

Microbiome related diseases such as Irritable bowel syndrome (IBS) and Inflammatory bowel diseases (IBD and drug resistant infections, may also be treated with FMT according to recent research. Even though FMT does not always work the same for conditions other than CDI ,these findings show that fixing the microbiome has become an important approach in modern treatments. The increasing challenge of antimicrobial resistance highlights the significance of alternative methods like FMT, which do not directly target pathogens but rather restore the gut's ecological balance

Even though FMT is very helpful it still comes with a few limitations. Variable clinical results and other rare problems like the transmission of harmful pathogens arise due to the absence of fixed standards for screening of donors, processing of stools and how FMT is administered. This shows the need for strict rules and better safety measures. Data on long-term safety is still limited, and continued research is crucial to comprehend the stability of microbial engraftment and the possible immunological or metabolic impacts of microbiota transfer .

In treating repeated CDI, FMT has turned out to be a major breakthrough and has also shown strong potential for treating a wide range of gut related diseases. Advancements in this area will depend on enhanced standardization, prolonged safety assessments, understanding the mechanisms of microbial interactions, and creating regulated, next-generation therapeutics based on microbiota. FMT could change from a treatment used mainly for CDI into a more common treatment for treating many gut related diseases, with more research and improvement.

8. ACKNOWLEDGEMENT

We would like to our special gratitude to the management of Kanpur Institute of Technology and the Department of Biotechnology.

9. REFERENCES

[1] E. van Nood, et al., “Duodenal infusion of donor feces for recurrent C. difficile,” New England Journal of Medicine, vol. 368, no. 5, pp. 407–415, 2013.

[2] G. Cammarota, G. Ianiro, H. Tilg, M. Rajilić–Stojanović, P. Kump, et al., “European consensus conference on fecal microbiota transplantation in clinical practice,” Gut, vol. 66, no. 4, pp. 569–580, 2017.

[3] L. C. McDonald, et al., “Clinical practice guidelines for Clostridium difficile infection,” Clinical Infectious Diseases, vol. 66, no. 7, pp. e1–e48, 2018.

[4] A. M. Seekatz and V. B. Young, “Clostridium difficile and the microbiota,” Journal of Clinical Investigation, vol. 124, no. 10, pp. 4182–4189, 2014.

[5] C. R. Kelly, et al., “FMT in immunocompromised patients,” American Journal of Gastroenterology, vol. 109, no. 7, pp. 1065–1071, 2015.

[6] M. N. Quraishi, et al., “FMT for recurrent CDI: A meta-analysis,” Journal of Hospital Infection, vol. 97, no. 3, pp. 239–249, 2017.

[7] S. Paramsothy, et al., “Long-term outcomes of FMT,” Lancet Gastroenterology & Hepatology, vol. 6, no. 4, pp. 271–281, 2021.

[8] M. D. Zilberberg, G. S. Tillotson, and L. C. McDonald, “CDI among hospitalized children,” Emerging Infectious Diseases, vol. 16, no. 4, pp. 604–609, 2010.

[9] Z. DeFilipp, P. P. Bloom, M. T. Soto, M. K. Mansour, M. R. A. Sater, et al., “Drug-resistant E. coli bacteremia after FMT,” New England Journal of Medicine, vol. 381, no. 21, pp. 2043–2050, 2019.

[10] U.S. Food and Drug Administration (FDA), “Fecal microbiota for transplantation: Safety communication,” 2019.

[11] Z. Kassam, C. H. Lee, Y. Yuan, and R. H. Hunt, “Fecal microbiota transplant success rate in CDI,” Clinical Gastroenterology and Hepatology, vol. 11, no. 4, pp. 528–534, 2013.

[12] C. M. Surawicz, et al., “Guidelines for CDI diagnosis and treatment,” American Journal of Gastroenterology, vol. 108, no. 4, pp. 478–498, 2013.

[13] A. Khoruts, et al., "Changes in microbial community structure post-FMT," Journal of Clinical Gastroenterology, vol. 44, no. 5, pp. 354–360, 2010.
[14] C. G. Buffie and E. G. Pamer, "Microbiota-mediated colonization resistance," Nature Reviews Immunology, vol. 13, no. 11, pp. 790–801, 2013.
[15] C. A. Lozupone, et al., "Diversity and stability of gut microbiota," Nature, vol. 489, no. 7415, pp. 220–230, 2012.
[16] E. Gough, H. Shaikh, and A. R. Manges, "Systematic review of intestinal microbiota in patients with C. difficile infection," American Journal of Gastroenterology, vol. 106, no. 4, pp. 932–941, 2011.
[17] Ferring Pharmaceuticals, "Rebyota (fecal microbiota, live-jslm) prescribing information," 2022.
[18] S. Khanna, et al., "A microbiome therapeutic prevents recurrent CDI," Journal of Infectious Diseases, vol. 225, no. 4, pp. 624–632, 2022.
[19] J. R. Allegretti, E. Zhao, R. Singh, and Z. Kassam, "Risk and standardization issues with FMT," Clinical Gastroenterology and Hepatology, vol. 17, no. 2, pp. 263–273, 2019.